Por favor, use este identificador para citar o enlazar este ítem:
http://ciatej.repositorioinstitucional.mx/jspui/handle/1023/708| Antimicrobial Peptide Elicitors (APEs) and Inhibitors (APIs): Challenges and Opportunities in Personalized Medicine | |
| ERNESTO PRADO MONTES DE OCA | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.19080/NAPDD.2017.02.555580 | |
| 2575-8942 | |
| "Antimicrobial Peptide Elicitors (APEs) and inhibitors (APIs) are physical (class I), chemical (class II) or biological agents (class III) that either up- or downregulate human antimicrobial peptide expression respectively. The up- or downregulation of antimicrobial peptides (APs) is related to the origin and/or severity of several diseases, including tuberculosis, HIV/AIDS, cancer and psoriasis among others which lead to opportunities for drug design. The development of these “first in class” molecules in the so-called “host-directed therapy”, together with companion diagnosticsoffer unique opportunities to increase efficacy and minimizing toxicity in future clinical settings. In this context, APIs and APEs could help in current treatment schemes with reduced risk of side effectsor in new schemes as e.g. MDR-TB clinical trials. The efficacy and safety of APEs and APIs remain to be demonstrated in the clinic, but this new class of molecules holds great opportunities to personalized medicine." | |
| Juniper Publishers | |
| 2017-06 | |
| Artículo | |
| Novel Approaches in Drug Designing & Development. 2017; 2(1): 555580 | |
| Inglés | |
| Bibliotecarios Estudiantes Investigadores | |
| Ernesto P M d O. Anti-microbial Peptide Elicitors (APEs) and Inhibitors (APIs): Challenges and Opportunities in Personalized Medicine. Nov Appro Drug Des Dev. 2017; 2(1): 555580 | |
| MEDICINA Y CIENCIAS DE LA SALUD | |
| Aparece en las colecciones: | ARTICULOS |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| NAPDD.MS.ID.555585.pdf | 391.05 kB | Adobe PDF | Visualizar/Abrir |